172 related articles for article (PubMed ID: 25784226)
21. Bortezomib-induced Sweet's syndrome.
Van Regenmortel N; Van de Voorde K; De Raeve H; Rombouts S; Van de Velde A; Lambert J; Schroyens W
Haematologica; 2005 Dec; 90(12 Suppl):ECR43. PubMed ID: 16464758
[TBL] [Abstract][Full Text] [Related]
22. Neutrophilic dermatosis complicating lenalidomide therapy.
Thieu KP; Rosenbach M; Xu X; Kist JM
J Am Acad Dermatol; 2009 Oct; 61(4):709-10. PubMed ID: 19577327
[TBL] [Abstract][Full Text] [Related]
23. Symmetrical Intertriginous and Flexural Exanthema due to Bortezomib (a Proteasome Inhibitor) Given for Myeloma.
Malissen N; Bourrain JL; Chiriac A; Montet A; Vincent L; Dereure O; Du-Thanh A
Acta Derm Venereol; 2016 Nov; 96(7):995-996. PubMed ID: 27001285
[No Abstract] [Full Text] [Related]
24. Bilateral phrenic nerve palsy induced by subcutaneous bortezomib in a patient with newly diagnosed multiple myeloma: first case reported.
López M; Martínez Lacasa X; Martí JM; Muntañola A; Fernández M; Huertas S; Saumell S; De Diego I; Bustamante G; Mesa A; Canet M; Julià M; Vall-Llovera F
Leuk Lymphoma; 2017 Feb; 58(2):482-484. PubMed ID: 27348085
[No Abstract] [Full Text] [Related]
25. Histiocytoid Sweet syndrome: a dermal infiltration of immature neutrophilic granulocytes.
Requena L; Kutzner H; Palmedo G; Pascual M; Fernández-Herrera J; Fraga J; García-Díez A; Yus ES
Arch Dermatol; 2005 Jul; 141(7):834-42. PubMed ID: 16027297
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic, Immunohistochemical, and Molecular Features of Histiocytoid Sweet Syndrome.
Alegría-Landa V; Rodríguez-Pinilla SM; Santos-Briz A; Rodríguez-Peralto JL; Alegre V; Cerroni L; Kutzner H; Requena L
JAMA Dermatol; 2017 Jul; 153(7):651-659. PubMed ID: 28296991
[TBL] [Abstract][Full Text] [Related]
27. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Schmidt-Wolf IG; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2015 Jul; 100(7):964-9. PubMed ID: 25840597
[TBL] [Abstract][Full Text] [Related]
28. The advantages of switch to subcutaneous bortezomib in the real life.
Mangiacavalli S; Cocito F; Ferretti VV; Ganzetti M; Cartia CS; Corso A
Leuk Lymphoma; 2018 Jun; 59(6):1505-1507. PubMed ID: 28980500
[No Abstract] [Full Text] [Related]
29. Two pediatric cases of nonbullous histiocytoid neutrophilic dermatitis presenting as a cutaneous manifestation of lupus erythematosus.
Camarillo D; McCalmont TH; Frieden IJ; Gilliam AE
Arch Dermatol; 2008 Nov; 144(11):1495-8. PubMed ID: 19015425
[TBL] [Abstract][Full Text] [Related]
30. Sweet syndrome with histiocytoid infiltrate and neutropenia: a rare combination.
Liu CI; Hsiao CH; Wu JT; Tsai TF
J Am Acad Dermatol; 2009 Nov; 61(5):882-4. PubMed ID: 19733935
[TBL] [Abstract][Full Text] [Related]
31. Pseudo-Gaucher cells in multiple myeloma.
Shenjere P; Roy A; Eyden B; Banerjee SS
Int J Surg Pathol; 2008 Apr; 16(2):176-9. PubMed ID: 18417675
[TBL] [Abstract][Full Text] [Related]
32. Histiocytoid Sweet syndrome harboring an isocitrate dehydrogenase 1 mutation: A case report and retrospective analysis of 29 cases of histiocytoid Sweet syndrome.
Libby TJ; Fleming K; Amin B
J Cutan Pathol; 2019 Apr; 46(4):290-292. PubMed ID: 30632174
[TBL] [Abstract][Full Text] [Related]
33. Development of acute pulmonary hypertension after bortezomib treatment in a patient with multiple myeloma: a case report and the review of the literature.
Akosman C; Ordu C; Eroglu E; Oyan B
Am J Ther; 2015; 22(3):e88-92. PubMed ID: 24100255
[TBL] [Abstract][Full Text] [Related]
34. Idiopathic histiocytoid Sweet syndrome: a case report with clinical and histopathological considerations.
Secchin P; Gomes MK; Quintella DC; Barata MCC; Machado HSV; Ramos-E-Silva M; Cuzzi T
Int J Dermatol; 2018 Oct; 57(10):1182-1186. PubMed ID: 30113066
[TBL] [Abstract][Full Text] [Related]
35. Immunoglobulin a multiple myeloma associated with sweet syndrome.
Tazi I; Nafil H; Mahmal L
J Cancer Res Ther; 2012; 8(4):652-3. PubMed ID: 23361295
[No Abstract] [Full Text] [Related]
36. Demyelinating polyradiculoneuritis in patients with multiple myeloma: the other side of bortezomib-induced neurotoxicity.
Gendreau S; Berzero G; Tafani C; Raynouard I; Ricard D; Malfuson JV; Viala K; Debs R; Houillier C; Diamanti L; Marchioni E; Lenglet T; Ouzegdouh M; Bihan K; Gilardin L; Psimaras D
Acta Oncol; 2020 Apr; 59(4):484-489. PubMed ID: 32122210
[No Abstract] [Full Text] [Related]
37. Sweet syndrome with aseptic splenic abscesses and multiple myeloma.
Sutton E; Groff R; Sutton LM
Cutis; 2018 May; 101(5):E27-E29. PubMed ID: 29894540
[No Abstract] [Full Text] [Related]
38. Sweet-like lesions induced by bortezomib: a review of the literature and a report of 2 cases.
Truchuelo M; Bagazgoitia L; Alcántara J; Velasco D; Carrillo R
Actas Dermosifiliogr; 2012 Nov; 103(9):829-31. PubMed ID: 22652505
[No Abstract] [Full Text] [Related]
39. Histiocytoid Sweet syndrome with ophthalmologic involvements: A novel association with uveitis.
Kato K; Namiki T; Tokoro S; Miura K; Yokozeki H
J Dermatol; 2017 Feb; 44(2):216-217. PubMed ID: 27177942
[No Abstract] [Full Text] [Related]
40. [Bortezomib-induced eruption: Sweet syndrome? Two case reports].
Thuillier D; Lenglet A; Chaby G; Royer R; Vaida I; Viseux V; Dadban A; Billet A; Christophe O; Chatelain D; Marolleau JP; Lok C; Damaj G
Ann Dermatol Venereol; 2009 May; 136(5):427-30. PubMed ID: 19442799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
